Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NAMS advanced for three days, in 202 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NAMS's RSI Indicator exited the oversold zone, 19 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NAMS as a result. In 60 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for NAMS turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 32 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for NAMS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.578) is normal, around the industry mean (3.498). P/E Ratio (-8.750) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. NAMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
SLDB saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 69 similar instances where the indicator turned positive. In 61 of the 69 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SLDB's RSI Indicator exited the oversold zone, 32 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for SLDB just turned positive on October 21, 2026. Looking at past instances where SLDB's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
Following a +8.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in 200 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for SLDB moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
SLDB broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SLDB entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.889) is normal, around the industry mean (3.498). P/E Ratio (-3.487) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SLDB | ||
|---|---|---|
OUTLOOK RATING 1..100 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 49 | |
P/E GROWTH RATING 1..100 | 20 | |
SEASONALITY SCORE 1..100 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| NAMS | SLDB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 66% | 2 days ago 80% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 81% |
| Advances ODDS (%) | 2 days ago 80% | 2 days ago 79% |
| Declines ODDS (%) | 10 days ago 78% | 10 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 87% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 88% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NAMS’s FA Score shows that 2 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NAMS’s TA Score shows that 4 TA indicator(s) are bullish while SLDB’s TA Score has 4 bullish TA indicator(s).
NAMS (@Biotechnology) experienced а -3.62% price change this week, while SLDB (@Biotechnology) price change was +14.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
NAMS is expected to report earnings on Mar 03, 2027.
SLDB is expected to report earnings on Mar 16, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with SLDB. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then SLDB could also see price increases.
| Ticker / NAME | Correlation To NAMS | 1D Price Change % | ||
|---|---|---|---|---|
| NAMS | 100% | +0.95% | ||
| SLDB - NAMS | 45% Loosely correlated | +2.14% | ||
| VKTX - NAMS | 45% Loosely correlated | -1.14% | ||
| IMVT - NAMS | 45% Loosely correlated | +1.59% | ||
| EDIT - NAMS | 44% Loosely correlated | -8.91% | ||
| FDMT - NAMS | 43% Loosely correlated | -0.16% | ||
More | ||||